Background Neoadjuvant PD-1 inhibitor therapy has shown promise in locally advanced head and neck squamous cell carcinoma (HNSCC), but only a subset of patients achieves major pathological responses. Liquid biopsy, the analysis of tumor-derived biomarkers in readily accessible bodily fluids (primarily blood), offers significant advantages over traditional tissue biopsies for predicting cancer treatment outcomes. The aim of this study is to develop a predictive model for neoadjuvant PD-1 therapy response in HNSCC patients using exclusively liquid biopsy approaches-namely, peripheral blood immune profiling (CyTOF) and plasma cytokine panels (Olink). Methods In a prospective trial involving 50 HNSCC patients treated with neoadjuvant tislelizumab plus chemotherapy, peripheral blood samples were collected pre- and post-treatment. Immune cell subsets were analyzed by mass cytometry (CyTOF), and circulating protein markers were quantified via a 92-plex targeted proteomics panel (Olink). Multimodal features were integrated into a predictive model using logistic regression. Results Baseline immune profiles differed significantly between responder (RD) and non-responder (NRD): RD showed higher frequencies of CD103−CD8+ central memory T cells (Tcm, c03) and elevated plasma interleukins (IL-5, IL-13), whereas NRD had more CD28−TIGIThighcPARP−CD8+ terminally differentiated effector memory CD45RA+ T cells (Temra, c17) and higher levels of chemokines (CCL3, CCL4) and MMP7. Neoadjuvant therapy reactivated both subsets, evidenced by downregulation of PD-1 and increased expression of activation markers (e.g., CD38) and cytotoxic mediators (e.g., granzyme B and interferon γ). A multimodal predictive model incorporating CD8+T cell subsets (c03, c17) and plasma biomarkers (IL-5, MMP7) demonstrated superior predictive accuracy (AUC = 0.9219). Conclusions Integrated peripheral immune profiling enables robust, noninvasive prediction of neoadjuvant PD-1 blockade efficacy in HNSCC. The identified immune cell subsets and plasma biomarkers provide a clinically applicable framework for early response stratification and personalized immunotherapy, supporting liquid biopsy as a viable platform for clinical decision-making. Trial registration Chinese Clinical Trial Registry, clinical trial number CHiCTR2200056354, 04 February 2022, <a href="https://www.chictr.org.cn/showproj.html?proj=151364">https://www.chictr.org.cn/showproj.html?proj=151364</a>. Graphical Abstract

Integrated peripheral blood multi-omics profiling identifies immune signatures predictive of neoadjuvant PD-1 blockade efficacy in head and neck squamous cell carcinoma

期刊论文
出版模式：

开放获取
发表日期：

2025年6月21日

查看全文

Hao Zhang,
Wenjie Wu,
Meng Wang,
Jie Zhang,
Chuanbin Guo,
Guojun Han,
Lin Wang

摘要

Background

Neoadjuvant PD-1 inhibitor therapy has shown promise in locally advanced head and neck squamous cell carcinoma (HNSCC), but only a subset of patients achieves major pathological responses. Liquid biopsy, the analysis of tumor-derived biomarkers in readily accessible bodily fluids (primarily blood), offers significant advantages over traditional tissue biopsies for predicting cancer treatment outcomes. The aim of this study is to develop a predictive model for neoadjuvant PD-1 therapy response in HNSCC patients using exclusively liquid biopsy approaches-namely, peripheral blood immune profiling (CyTOF) and plasma cytokine panels (Olink).

Methods

In a prospective trial involving 50 HNSCC patients treated with neoadjuvant tislelizumab plus chemotherapy, peripheral blood samples were collected pre- and post-treatment. Immune cell subsets were analyzed by mass cytometry (CyTOF), and circulating protein markers were quantified via a 92-plex targeted proteomics panel (Olink). Multimodal features were integrated into a predictive model using logistic regression.

Results

Baseline immune profiles differed significantly between responder (RD) and non-responder (NRD): RD showed higher frequencies of CD103⁻CD8⁺ central memory T cells (Tcm, c03) and elevated plasma interleukins (IL-5, IL-13), whereas NRD had more CD28⁻TIGIT^highcPARP⁻CD8⁺ terminally differentiated effector memory CD45RA⁺ T cells (Temra, c17) and higher levels of chemokines (CCL3, CCL4) and MMP7. Neoadjuvant therapy reactivated both subsets, evidenced by downregulation of PD-1 and increased expression of activation markers (e.g., CD38) and cytotoxic mediators (e.g., granzyme B and interferon γ). A multimodal predictive model incorporating CD8⁺T cell subsets (c03, c17) and plasma biomarkers (IL-5, MMP7) demonstrated superior predictive accuracy (AUC = 0.9219).

Conclusions

Integrated peripheral immune profiling enables robust, noninvasive prediction of neoadjuvant PD-1 blockade efficacy in HNSCC. The identified immune cell subsets and plasma biomarkers provide a clinically applicable framework for early response stratification and personalized immunotherapy, supporting liquid biopsy as a viable platform for clinical decision-making.

Trial registration Chinese Clinical Trial Registry, clinical trial number CHiCTR2200056354, 04 February 2022, https://www.chictr.org.cn/showproj.html?proj=151364.

Graphical Abstract